Patent intelligence · US
US 11802110
2-amino-N-(arylsulfinyl)-acetamide compounds as inhibitors of bacterial aminoacyl-tRNA synthetase
2-amino-N-(arylsulfinyl)-acetamide compounds as inhibitors of bacterial aminoacyl-tRNA synthetase
Patent details — US 11802110
- Jurisdiction
- US
- Status
- granted
- Grant date
- Oct 31, 2023
- Expiration
- Oct 26, 2043
- Applicant
- Oxford Drug Design Limited
- Claims
- 28
- CPC classes
- A61P, A61P1/02, A61P1/04, A61P11/04
Quick answer
US 11802110 (2-amino-N-(arylsulfinyl)-acetamide compounds as inhibitors of bacterial aminoacyl-tRNA synthetase) is held by Oxford Drug Design Limited. Status: granted. Granted Oct 31, 2023. Expires Oct 26, 2043 (17 years remaining) — relevant for patent-cliff and LOE planning.
Key facts
- Applicant
- Oxford Drug Design Limited
- Grant date
- Expiration
- Claims
- 28
- CPC classes
- A61P, A61P1/02, A61P1/04, A61P11/04, A61P13/00, A61P13/02
More from Oxford Drug Design Limited
Related pharmaceutical patents in our USPTO index.
-
US 12378245
Crystalline forms of an RSK inhibitor
granted -
US 12297243
Methods and compositions for reducing the immunogenicity of chimeric notch receptors
granted -
US 12291058
Dispersions for additive manufacturing comprising discrete carbon nanotubes
granted -
US 12268695
Betulin-containing birch bark extracts and their formulation
granted -
US 12247004
2-amino-N-(amino-oxo-aryl-lambda6-sulfanylidene)acetamide compounds and their therapeutic use
granted -
US 12065498
Methods of making bispecific anti-CD307E and anti-BCMA chimeric antigen receptors and uses of the same
granted -
US 12005194
Configurable oxygen concentrator and related method
granted -
US 11998571
Pharmaceutical composition comprising stem cell-conditioned medium and exosome isolated therefrom as active ingredient for prevention or treatment of ocular disease
granted
Frequently asked questions
What is US patent 11802110?
US 11802110 (2-amino-N-(arylsulfinyl)-acetamide compounds as inhibitors of bacterial aminoacyl-tRNA synthetase) is held by Oxford Drug Design Limited. Status: granted. Granted Oct 31, 2023. Expires Oct 26, 2043 (17 years remaining) — relevant for patent-cliff and LOE planning.
Who owns US 11802110?
Oxford Drug Design Limited is listed as the applicant in USPTO PatentsView records indexed by NovaPharmaNews. We track 201 pharmaceutical patents for this assignee.
When does US 11802110 expire?
Our index shows an expiration date of Oct 26, 2043 (17 years from today). Confirm material dates against USPTO, FDA Orange Book, or qualified counsel before contractual decisions.